Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Investor Presentation (May 2023)
31 slides from Poly Medicure's investor presentation, May 2023

Slide 1: Investors Presentation May 2023
Investors Presentation May 2023 www.polymedicure.com Confidential I Slide 1

Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in w

Slide 3: Table of Contents
Table of Contents Polymed at a Glance 4 Board of Directors 9 Manufacturing Excellence 11 Research and Development 15 Sustainability Reporting 17 Financial Data 19 Medical Devices Policy 2023 23 Way Forward 26 Capex Update 27 Awards and Corporate Communication 28 www.polymedicure.com Confidential I S

Slide 4: Polymed at a Glance
Polymed at a Glance 300+ 125+ INR 1115 Crores 30+ 160+ Sales Associates Countries Consolidated Revenue Clinical Specialists Medical Devices Largest Exporter of 3000+ 1 Billion+ consumable Medical devices, Devices Manufacturing Employee Base 9 yrs in a row Capacity per year www.polymedicure.com Confi

Slide 5: Portfolio of more than 160+ Medical Devices
Polymed’s Unique Position EMINENCE IN FLUID MANAGEMENT DISPOSABLES AND PROCEDURAL MEDICAL DEVICES COMPREHENSIVE PRODUCT RANGE Oncology Infusion & Vascular Access Molecular Diagnostics Gastroentrology Urology Critical Care Renal Care & Anaesthesia & Dialysis Respiratory Care Surgery and Wound Drainag

Slide 6: Our Journey
Our Journey…..….. A SUCCESSFUL STORY SPANNING OVER 25 YEARS 1997 2001 2002 2004 2007 2009 2011 Commencement of Expansion of JV in Egypt Faridabad Plant-2 New Plant China Plant Company Manufacturing Faridabad Plant Extension (100% Haridwar Listed in NSE Operation EOU) 2014 2016 2018 2020 2021 *2023 *

Slide 7: Corporate Structure
Corporate Structure POLYMED GROUP INDIA OVERSEAS Poly Medicure Poly Medicure BV- Ultra for Medical (Laiyang) Co. Ltd. Netherlands Poly Medicure Ltd Products Co. China Wholly owned (UMIC) – Egypt Holding Co. Wholly owned Subsidiary Associate (23%) Subsidiary (100%) (100%) Plan 1 Health India Pvt. Ltd

Slide 8: 2020-2025 Vision
2020-2025 Vision TRANSFORM FROM A PRODUCT COMPANY TO A SOLUTION PROVIDER ORGANIZATION Started in 1997 2002-2009 2011-2019 2020-2021 2022-2025 2026 and beyond Commencement of Product and facility New R&D Center • Focus on commercial • Launch differentiated • Globally recognized Manufacturing expansio

Slide 9: Board of Directors & Management
Board of Directors & Management Mr. Devendra Raj Mehta (Chairman, Non-Executive Independent Director) Mr. Himanshu Baid Mr. Rishi Baid (Managing Director) (Joint Managing Director) Mrs. Mukulika Baid Dr. Shailendra Raj Mehta Mr. Jugal Kishore Baid (Non-Executive Director) (Non-Executive (Non-Executi

Slide 10: Executive Global Leadership
Executive Global Leadership Building out Geographical Leadership with strong medical device experience & expertise Heyward Powe Xue Wendong VP Sales & Business General Manager , China Development, North & Central America Alessando Balboni Prof. Sergio Bertoglio • 20 years Medical Device • 24 years M

Slide 11: Across the World, We serve people in over 125+ countries
Across the World, We serve people in over 125+ countries Our Growth Verticals 4 new Plants under Construction UNIQUELY POSITIONED TO PROVIDE VALUE TO OUR CUSTOMERS www.polymedicure.com Confidential I Slide 11

Slide 12: Manufacturing
Manufacturing (INDIA, ITALY, EGYPT, CHINA) 1st Medical Device Company from India to have overseas plants. Faridabad Plant, India Haridwar Plant, India IMT Faridabad India Over 300+ Moulding Machines & 1200+ Injection Molds More than 200+ automatic Faridabad Plant, India Jaipur Plant, India R & D Cen

Slide 13: Manufacturing Excellence
Manufacturing Excellence www.polymedicure.com Confidential I Slide 13

Slide 14: Manufacturing Excellence
Manufacturing Excellence www.polymedicure.com Confidential I Slide 14

Slide 15: Research and Development Capabilities
Research and Development Capabilities Product Design Tooling • Mold Design & & Development Development • Product Design using CAD Software ProE Creo, • Mold Flow Analysis for Solidworks, NX, AutoCAD simulation 1 2 • Dedicated R&D Quality Lab • VMC, CNC machines for Design Verification EDM/Wirecut/Mi

Slide 16: Research and Development Capabilities: Manufacturing Process
Research and Development Capabilities Manufacturing Process Processing capabilities • Cannula manufacturing • Injection Molding • Ultrasonic Welding Horizontal M/C’s • Radio Frequency Welding • Insert Molding (Vertical M/C’s) • Thermal Bonding • Extrusion (PVC, PU, FEP) • Hot Air Welding • Laser Wel

Slide 17: Sustainability & MDSAP Certifications
Sustainability & MDSAP Certifications ISO-14001 MDSAP www.polymedicure.com Confidential I Slide 18

Slide 18: Stickiness in customer base & sustainable business
Stickiness in customer base & sustainable business LEVERAGE OUR (CUSTOMER) INSTALLED BASE AND DISTRIBUTOR NETWORK TO LAUNCH NEW PRODUCTS Polymed Sales By Geography Polymed Sales By Product Category Polymed Brand and OEM Private Label Sales 9% 7% 30% 32% 3% 4% 10% 68% 67% 70% 4% 3% Export India Infus

Slide 19: Our Strength: Consistent all-round growth (Consolidated)
Our Strength: Consistent all-round growth (Consolidated) ₹ ₹ ₹ REVENUE (₹ Crs) EBIDTA (₹ Crs) PBT (₹ Crs) PAT (₹ Crs) 1200.00 1115.23 923.06 300.00 269.38 250.00 237.49 200.00 179.28 1000.00 786.20 250.00 195.24 800.00 214.34 213.10 200.00 180.04 150.00 135.84146.51 200.00 600.00 150.00 150.00 100.0

Slide 20: Creating Value for Shareholders
Creating Value for Shareholders Increasing Shareholders Base Creating Value for Shareholders NO. OF SHAREHOLDERS MARKET CAP IN INR (CRS) 40000 35393 10000 9105.74 9140.14 33831 9000 35000 7884.74 8000 30000 7000 25000 21531 6000 20000 5000 15000 4000 10000 8574 3000 2056.36 2000 5000 1000 0 0 No of

Slide 21: Ratios
Ratio’s Interest Coverage Debt Service Coverage 70 64.53 12 9.91 60 10 50 41.34 8 6.87 40 5.55 29.58 6 4.61 30 20 14.32 4 10 2 0 0 % % FY 2020 FY 2021 FY 2022 FY 2023 FY 2020 FY 2021 FY 2022 FY 2023 ROCE 30.00% 21.03% 20.00% 15.49% 14.05% 16.47% 10.00% 0.00% % FY 2020 FY 2021 FY 2022 FY 2023 * Incre

Slide 22: Performance Standalone/Consolidated
Performance Standalone/Consolidated Poly Medicure Ltd 1068.05 Standalone in INR Crs Consolidated in INR Crs 1115.23 1200.00 1200.00 879.36 923.06 1000.00 1000.00 747.38 786.20 800.00 800.00 600.00 600.00 268.48 400.00 269.38 236.88 400.00 237.49 212.13 208.30 194.72 214.34 213.10 179.04 195.24 173.3

Slide 23: New National Medical Devices Policy 2023
New National Medical Devices Policy 2023 Vision: ✓ Accelerated growth path with a patient-centric approach ✓ To emerge as the global leader in the manufacturing and innovation of medical devices by achieving 10-12% share in the expanding global market over the next 25 years. ✓ Policy is expected to

Slide 24: New National Medical Devices Policy 2023
New National Medical Devices Policy 2023 Strategies to Promote Medical Device Sector: • Regulatory Streamlining: creation of a Single Window Clearance System, enhancing the Role of BIS and designing a coherent pricing regulation. • Enabling Infrastructure: The establishment and strengthening of larg

Slide 25: Production Linked Incentive Scheme (I & II)
Production Linked Incentive Scheme (I & II) • Polymed got approval under Renal Care Segment.New Cardio range to be added • Committed Investment of 70 Crs under the scheme from FY 2022-28 • 25.5 Crs of Investment done upto Mar-23 under the scheme • Polymed got approval under In Vitro Diagnostic Medic

Slide 26: Way Forward
Way Forward … International Strategy Vascular Access • Transition to MDR • Be a leading global player 04 • Improve Brand visibility in • Expand footprint in Europe & International markets USA 01 • Received US FDA 510(K) clearance for two products Renal Promote Infection • Introduce Indigenous Dialys

Slide 27: Capex Update
Capex Update • Capex incurred in FY 2022-23 : INR 237 Crs • Capex planned for FY 2023-24 : INR 200 Crs Faridabad Manufacturing and Premises under Construction as on 31st March 2023 Warehouse 56A Scheduled Operation Q1 -2023-24 Jaipur SEZ Phase - II Faridabad Plant 117 Faridabad IMT Plant II Schedule

Slide 28: Awards & Recognition
Awards & Recognition “Top 50 Innovative Companies Award 2022” By Confederation of Indian Industry – Received in December 2022 www.polymedicure.com Confidential I Slide 28

Slide 29: Corporate Communication
Corporate Communication Media I Industry Events I Webinars| Social Media I Clinical Engagements I Conferences 1 lac + followers on social media, 250 posts pushed last year Annual Summit 2022 www.polymedicure.com Confidential I Slide 29

Slide 30: Corporate Communication
Corporate Communication Media I Industry Events I Webinars| Social Media I Clinical Engagements I Conferences ARAB HEALTH 2023, Dubai MEDICA 2022, Germany INS Annual Conference 2022, Delhi ISNCON 2022, Pune www.polymedicure.com Confidential I Slide 30

Slide 31: Thank You
Poly Medicure Limited Thank You Registered Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com www.polymedicure.com Confidential I Sli
Source: Internet Archive copy of polymedicure.com
More decks from Poly Medicure Limited
Q2 FY2027 Earnings Presentation34 slides · Nov 5, 2026
Q2 FY27 Earnings Presentation34 slides · Nov 5, 2026
Shareholder Meeting (September 2026)22 slides · Sep 5, 2026
Q1 FY27 Earnings Presentation29 slides · Aug 7, 2026
Q1 FY27 Earnings Presentation30 slides · Aug 7, 2026
Q4 FY26 Earnings Presentation43 slides · May 25, 2026